Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Lung Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Lung cancer patients with PET/CT or CT examination before any cancer-specific treatment

Yang Jin, MD

The investigators will evaluate the utility of computer aided image analysis in lung cancer with the aim of predicting treatment response and prognosis.

Tumor biological behavior is the fundamental cause of heterogeneous prognosis. The features found on medical images are also reflections of the tumor biological behavior. However, the limitations in spatial and intensity resolution of the naked eye are two inevitable shortcomings of image interpretation by naked eyes, resulting in subjective and limited analyses of images. Computer aided image analyses such as radiomic analysis and machine learning methods are emerging as promising image interpretation methods. The natural advantage of the unlimited spatial and intensity resolution of computers can overcome the shortcomings of visual inspection with the naked eye. Moreover, the massive computing power of computer is also far greater than that of humans. This study will focus on the application of computer aided analysis in predicting treatment response and prognosis in lung cancer.

Clinical Significance of Computer Aided Image Analysis in Treatment Response Evaluation of Lung Cancer

The interval between the date of diagnosis and death

The interval between the date of treatment initiation and disease progression

Wuhan Union Hospital, China

Professor

Other Dietary Supplements

All Drugs and Chemicals

Pyruvate

Participants will receive an injection of 250 mM of hyperpolarized 13-C pyruvate intravenously after standard of care imaging sequences are performed. Then participants will undergo HP-MR imaging.

Imaging tumors pre and post administration of hyperpolarized 13-C pyruvate injection.

Hyperpolarized 13C-Pyruvate

Nikita Rednam, BA

Many human diseases are characterized by their ability to alter existing metabolic pathways and interrupt cellular processes. Cancer exploits the Warburg effect and utilizes greater glucose than normal cells and within this process uses anaerobic respiration, leading to increased conversion of pyruvate to lactate. This can be exploited by hyperpolarized imaging. Hyperpolarized 13C MRI imaging is an approach that utilizes a stable isotope of Carbon (13C) linked to pyruvate. MRI spectroscopy is used in conjunction with hyperpolarized 13C pyruvate in order to temporally detect pyruvate and its conversion to lactate in-vivo, in order to visualize downstream metabolic (glycolytic) activity secondary to the Warburg effect, which should be useful in detecting and characterizing tumors of various types. Hyperpolarized 13C pyruvate MR imaging has not been tested in most cancers. In this preliminary survey, we will test the hypothesis that hyperpolarized 13C pyruvate MR imaging can be used to image various cancers.

Most cancers exhibit the Warburg effect, which involves synthesis of lactate via glycolytic pathways. The present method of using 18F-FDG to image metabolic events only evaluates early glycolysis and does not investigate late glycolytic effects which can be examined by 13C pyruvate. The ability to detect cancer using 13C pyruvate has been shown using ovarian cancer models and in the prostate in humans, however its utility in other tumors needs clarification. Because cancers of various types affect metabolic pathways, it is necessary to improve imaging techniques to better investigate downstream metabolism. Many studies have shown that there are higher lactate levels in cancer tissue and higher levels of glycolysis. 13C pyruvate imaging takes advantage of these pathways by imaging the tumors while undergoing pyruvate to lactate conversion . From this modality, a three dimensional visualization of the tumor and metabolic products created by the pyruvate can be investigated.

Participants will be evaluated pre and post hyperpolarized 13-C pyruvate injection for change in pyruvate signal compared to background.

HP Pyruvate MRI in Cancers

Hyperpolarized 13-C Pyruvate MRI Surveillance of Multiple Cancers

University of Maryland, Baltimore

Chief of Oncologic Imaging

Skin and Connective Tissue Diseases

Breast Neoplasms

Breast Diseases

Skin Diseases

Patients who underwent total mastectomy (including simultaneous reconstruction surgery) through preoperative examinations (MRI, breast ultrasound, mammography, etc.) after receiving neoadjuvant chemotherapy

Patients who underwent total mastectomy (including simultaneous reconstruction surgery) through preoperative examinations (MRI, breast ultrasound, mammography, etc.) even in patients who did not receive neoadjuvant chemotherapy as a control group.

MRI, Breast ultrasound sonography, mammography

Preoperative imaging study

* The surgical method for breast cancer is determined according to the size and location of the remaining lesions after prior chemotherapy.
* There are many patients who were able to undergo partial resection when confirming the final results of patients who underwent total resection after prior chemotherapy.
* Therefore, we would like to investigate whether it is effective to make decisions based on the results of pre-operative tests after prior chemotherapy.

In a study published by Jennifer F. et al., sensitivity to lesions remaining after prior chemotherapy of breast magnetic resonance imaging was measured as 83%, specificity 47%, PPV 47%, NPV 83%, and accuracy 74%. have.

Most of the preoperative examinations after prior chemotherapy have the most confidence in the results of breast magnetic resonance imaging, but there will be other factors to predict this result as there will be differences in the actual postoperative pathology results. .

After prior chemotherapy, total resection was performed, and cases where partial resection is possible in the postoperative pathologic results are prospectively identified and compared and analyzed.

Unnecessary Mastectomy Due to False Size Prediction by Preoperative Imaging Studies in Breast Cancer

The Percentage of Unnecessary Mastectomy Due to False Size Prediction by Preoperative Imaging Studies in Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy

Comparison of the difference in size of lesions confirmed by preoperative imaging and final pathology results

Seoul National University Hospital

Carcinoma

Carcinoma in Situ

Carcinoma, Ductal

Carcinoma, Intraductal, Noninfiltrating

Carcinoma, Ductal, Breast

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Breast Carcinoma In Situ

Breast DCIS patients who diagnosed by tissue biopsy except excisional biopsy before surgery, and who agreed to taking the breast MRI.

Contrast-enhanced MRI will be performed on patients diagnosed with ductal carcinoma in-situ (DCIS) by preoperative biopsy.

contrast-enhanced breast MRI

Hyeong-Gon Moon

It is considered that whether or not the accompanying invasive cancer classified through MRI images of breast cancer patients identified as Ductal Carcinoma in situ (DCIS) through preoperative tissue biopsy is significantly consistent with the postoperative stage.

Therefore, this study intend to evaluate the effectiveness as a diagnostic tool that can help determine the axillary lymph node surgery by predicting the possibility of post-operative up-staging using magnetic resonance imagings of breast cancer patients who have been identified as ductal carcinoma in situ and are scheduled for surgery.

1. To date, there is no significant research data on the value of the Apparent Diffusion Coefficient (ADC) that can distinguish between pure Ductal Carcinoma in situ (pure DCIS) and invasive cancer (DCIS-IC), from June 2019 to 2020 1 Of the 144 patients who obtained Diffusion Weighted images (b=0,800,1200) with 3.0-T MRI equipment and diagnosed with ductal carcinoma in situ on the biopsy, among 144 patients who did not undergo preoperative chemotherapy using a CAD program, the 3-dimensional Apparent Diffusion Coefficient value of the tumor is measured and compared with whether or not there is invasive cancer after surgery, and the optimal Apparent Diffusion Coefficient reference value that can predict the invasive cancer will be retrospectively derived.
2. Scheduled MRI tests will be performed on patients enrolled from July 2020, and will be performed using the standard protocols (3T, contrast enhancement and diffuse enhancement images DWI b0,800,1200). Among the MRI images taken, the range of lesions is evaluated in contrast-enhanced T1-highlighted images, and the Apparent Diffusion Coefficient values of the lesions are three-dimensionally mapped using a CAD program and histogram analysis on diffused images. The ADC reference value derived from the retrospective analysis is used to predict prospectively for invasive cancer in all lesions.
3. Mastectomy is performed according to the existing surgical method. Axillary lymph node surgery is determined according to the existing decision method (tumor location, size, range, histological grade, etc.).

Prediction of Upgrade to Invasive Cancer in Patients Diagnosed With Ductal Carcinoma in Situ by Percutaneous Core Needle Biopsy

Prediction of Upgrade to Invasive Cancer in Patients Diagnosed With Ductal Carcinoma in Situ by Percutaneous Core Needle Biopsy: A Development and Validation Study

Analysis of the concordance rate (%) of invasive cancers confirmed in the final histopathology after surgery.

Analysis the proportion of up-staging(%) of invasion cancer in the final histopathology.

associate professor

Digestive System Diseases

Rare Diseases

Stomach Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Stomach Diseases

Stomach Cancer

This group comprises participants diagnosed with advanced gastric cancer. The participants will be treated with standard neoadjuvant chemotherapy regimens recommended by clinical guidelines. Treatment details, including the generic name of the drugs, dosage form, dosage, frequency, and duration, will be recorded according to the specific regimen.

Participants in this group are diagnosed with gastric cancer and are scheduled to undergo neoadjuvant chemotherapy as a part of their treatment regimen. The specific chemotherapy drugs, dosages, and schedules will be determined according to established clinical guidelines and the participant's specific condition.

Neoadjuvant Chemotherapy

Di Dong, Ph.D.

Xinming Zhao

Zhenyu Jin

Lei Tang

Yi Wang

Weihua Liao

Yangming Li

Changming Huang

Shuzhong Cui

Shenping Yu

Guoxin Li

Xiaochun Meng

Zhenhui Li

Guanqiao Jin

Hexiang Wang

Jun Zhang

Zhenning Wang

Jie Bao

Zhaoxiang Ye

Jing Li

Jianbo Gao

Xiuhong Shan

Francesco De Cobelli

Yali Zang, Ph.D.

This study seeks to develop a deep-learning-based intelligent predictive model for the efficacy of neoadjuvant chemotherapy in gastric cancer patients. By utilizing the patients' CT imaging data, biopsy pathology images, and clinical information, the intelligent model will predict the post-neoadjuvant chemotherapy efficacy and prognosis, offering assistance in personalized treatment decisions for gastric cancer patients.

This study seeks to develop a deep learning model to predict the outcomes of neoadjuvant chemotherapy in patients with gastric cancer. Leveraging participants' CT scans, biopsy pathology images, and clinical profiles, this model aims to forecast the effectiveness of post-neoadjuvant chemotherapy and the subsequent prognosis, thereby aiding in individualized treatment choices for these participants.

Data Collection: The investigators will gather data from 1,800 retrospective cases and 200 prospective cases from multiple hospitals. The retrospective data will be divided into training and testing sets to train and validate the model, respectively. The model's performance will subsequently be evaluated using the prospective dataset.

Clinical Information: This encompasses the participant's gender, age, tumor markers, staging, type, specific treatment plans, pre and post-treatment lab results, etc.

Imaging Data: CT imaging data taken within one month prior to the neoadjuvant chemotherapy, with at least the venous phase CT imaging included.

Pathology Data: Pathology images from a gastric tumor biopsy stained with Hematoxylin and Eosin (HE) taken within one month prior to treatment.

TRG Grading: Based on the pathology report of the surgical samples using the Ryan TRG grading system.

Prognostic Endpoints: The recorded endpoints are a 3-year progression-free survival (PFS) and a 5-year overall survival (OS). All deaths due to non-disease factors are excluded from the prognosis analysis.

The biospecimens consist of gastric tumor biopsy samples, collected from each patient prior to the initiation of neoadjuvant chemotherapy. These specimens undergo HE (Hematoxylin and Eosin) staining for pathology imaging.

AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy

Deep Learning-Based Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy

Individual participant data (IPD) may be made available to other researchers upon request. Interested researchers should present a reasonable research proposal and a data usage application. All participating units of this study will review and assess the proposal and application to determine whether to share the data.

The AUC will be used to evaluate the performance of the AI model in predicting TRG grading of gastric cancer patients after neoadjuvant chemotherapy. An AUC of 1 indicates perfect prediction, while an AUC of 0.5 indicates prediction no better than chance.

Accuracy measures the proportion of true positive and true negative predictions made by the AI model among all predictions. It indicates the capability of the model to correctly classify patients into their respective TRG gradings.

The duration from the date of patient confirmation to the date of tumor progression or death of the patient, whichever occurs first.

The duration from the date of patient confirmation to the date of death of the patient.

Peking University Cancer Hospital & Institute

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Yunnan Cancer Hospital

Henan Cancer Hospital

Zhenjiang First People's Hospital

First Hospital of China Medical University

Cancer Hospital of Guangxi Medical University

Peking University People's Hospital

Tianjin Medical University Cancer Institute and Hospital

The First Affiliated Hospital of Zhengzhou University

Nanfang Hospital, Southern Medical University

The Affiliated Hospital of Qingdao University

Ruijin Hospital

Sixth Affiliated Hospital, Sun Yat-sen University

Peking Union Medical College Hospital

Xiangya Hospital of Central South University

Affiliated Cancer Hospital & Institute of Guangzhou Medical University

The First Affiliated Hospital of Soochow University

First Affiliated Hospital, Sun Yat-Sen University

Fujian Medical University Union Hospital

Fujian Cancer Hospital

San Raffaele University Hospital, Italy

Chinese Academy of Sciences

Symptoms and General Pathology

Neoplasm Metastasis

Liver Neoplasms

Neoplastic Processes

Liver Diseases

Hematinics

Liver Extracts

In total 10 patients will be included who are scheduled for resection of colorectal liver metastases and receive SGM-101 and ICG

SGM-101 op top of ICG

Mats Warmerdam, Msc

This will be the first trial testing the feasibility of working simultaneously with the two fluorescent dyes ICG and SGM-101 in 10 patients with colorectal metastases.

25-30% of patients with colorectal cancer develop colorectal liver metastases (CRLM). Cornerstone for optimal survival is achieving radical surgical resections of all metastases . To assist the surgeon in achieving this, the use of intra-operative ICG for fluorescent tumour delineation has widely been adopted as standard of care. Multiple international trials have demonstrated that the use of ICG increases the rate of radical resections and result in the detection of additional malignant lesions invisible to the naked eye. However, the rate of false positives is still high and although it has increased the number of radical resections, even in a minimal invasive cohort the unintended R1 rate is still as much as 8%. Therefore, there is a need of an additional real-time intra-operative tool to detect R1 resections, especially in patients with a priori high risk for R1. To illustrate, in a large shared database of the Erasmus University Medical Center was found that patients that either received neoadjuvant chemotherapy, underwent a resection for \>3 CRLM or patients that had a locally recurrent liver metastasis were independently associated with high R1 rates, ranging between 23-29%. Therefore, here is proposed the addition of SGM-101, a tumour targeted (carcinoembryonic antigen, CEA) NIR-fluorescence probe to ICG in patients scheduled for a resection with high risk of R1, ultimately to reduce the R1 ratio. This is the first trial testing the feasibility of working simultaneously with the two fluorescent dyes. If feasibility is met in this trial, this is a step-up towards a powered trial with primary objective to reduce the rate of R1 resections.

An additional exploratory objective of this study is to investigate the feasibility of SGM-101's potential to isolate circulating tumour cells (CTCs) and tumour-derived extracellular vesicles (EVs) as biomarkers for CRC. The load of CTCs and EVs in the circulation is strongly associated with poor clinical outcomes. Studies have shown that they contain information about the molecular profile of the tumour. The administration of SGM-101 may enable the detection of CEA positive CTCs and EVs.

In total 10 patients will be included who are scheduled for resection of colorectal liver metastases and meet at least one of the following criteria:

1. Scheduled for resection of \>3 CRLM or,
2. Completed neo-adjuvant chemotherapy, of which the last course was completed within 3 months before surgery or,
3. Scheduled for surgery because of a locally recurrent liver metastasis.

Fluorescence-guided Resection Of Colorectal Liver Metastases Using SGM-101 and Indocyanine GREEN

Data will be coded and available only to the researchers of the LUMC on this particular trial. No other people will get access to the data. Results will be published.

It is deemed feasible when it meets all of the following criteria:

1. A positive score on practical workability measured with survey A 'practical workability during surgery'
2. A positive score on the patient's experience measured with survey B 'patient experience'.
3. SGM-101: at least 80% sensitivity, measured as follows:

   * For capsular lesions, that are visible in white light are counted positive if TBR ≥ 1.5 in vivo.
   * For subcapsular lesions that are not visible in white light will be counted as positive if:

   A: TBR ≥ 1.5 in vivo, OR B: TBR ≥ 1.5 ex vivo on whole specimen or on bread loafs
4. No cross-interference of fluorescent signal of both dyes within the two different excitation and emission channels.

Feasibility is reached when a positive result on all four items is scored.

Leiden University Medical Center

MD, PhD, principle investigator

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Carcinoma, Transitional Cell

Ureteral Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Ureteral Diseases

Urologic Diseases

Male Urogenital Diseases

Transitional Cell Carcinoma

The extracted DNA from morning urine will be analyzed by UroCAD to determine the level of CNV. CTU and cytology will be performed according to the routine of clinical practice (N=80).

Patients need to undergo CTU examination and being treated for benign diseases with ureteroscopy, but without any tumor will provide a negative control to provide data for determining the sensitivity and specificity of UroCAD, CTU and cytology assay (N=30).

The extracted DNA from morning urine will be analyzed by UroCAD to determine the level of CNV. CTU and cytology will be performed according to the routine of clinical practice.

UroCAD assay, CTU examination and urine cytology

Shuxiong Zeng, M.D., Ph.D

Shuxiong Zeng, M.D. Ph.D

Chuangliang Xu, M.D., Ph.D

Upper tract urothelial carcinoma (UTUC) diagnosis include urography using computed tomography urography (CTU) or urography using MRI (MRU). The sensitivity of CTU decreases substan¬tially with decreasing lesion size. Other drawbacks of CTU include the radiation exposure and potential adverse effects in patients with allergic reactions or pre-existing renal impairment. In terms of urine cytology, the major drawbacks of urine cytology are low sensitivity and highly dependent of the experience and skills of the cytopathologist. We here intended to investigate whether UroCAD can be added in the diagnostic work-up of UTUC patient, and improve the accuracy of predicting UTUC before surgery.

The recommendations for imaging in UTUC diagnosis include urography using CTU or MRU. In the standard diag¬nostic work up, urine cytology and a cystoscopy to rule out a concomitant bladder tumor are also advised. In addition, diagnostic ureterorenoscopy and biopsy are advised in patients in whom the findings of these pro¬cedures could influence treatment decisions, The sensitivity of CTU decreases substan¬tially with decreasing lesion size. For polypoid tumors of 5-10 mm maximal diameter, CTU has a high sensitivity and specificity, but sensitivity decreases to 89% for lesions \<5 mm and further to 40% for lesions \<3 mm. Flat lesions are even more difficult to diagnose. Other drawbacks of CTU include the radiation exposure and the need for intravenous contrast media with accompa¬nying potential adverse effects in patients with allergic reactions or pre-existing renal impairment. In terms of urine cytology, the major drawbacks of urine cytology tests: the sensitivity of positive urine cytology is highly dependent on tumor grade and decreases to 12% for low-grade tumors and 15% for non-invasive stage Ta tumors. Hence, low-grade urothelial tumors cannot be reliably detected by urine cytology. Finally, the accuracy of the cytology findings is highly dependent of the experience and skills of the cytopathologist. Our previous study has proved that UroCAD, which is able to detect chromosomal aberrations of the urine exfoliated cells, is a reliable method in diagnosing urothelial carcinoma with sensitivity and specificity of 82.5% and 96.9%, respectively. But its potential role in diagnosis of UTUC in combination with CTU and cytology hasn't been assessed yet and the accuracy of UroCAD in detecting UTUC still need to be further validated. We here intended to investigate whether UroCAD can be added in the diagnostic work-up of UTUC patient, and improve the accuracy of predicting UTUC before surgery.

UroCAD Assay Combined With Computed Tomography Urography and Urine Cytology for UTUC Diagnosis.

A Prospective, Single-blinded Study of UroCAD Assay Combined With Computed Tomography Urography and Urine Cytology for UTUC Diagnosis.

To pretect the personal privacy of participants and the genetic sequencing information, IPD data will not be shared.

Number of patients "declared positive" with the UroCAD assay, CTU or cytology among the patients suffered from UTUC and number of patients "declared negative" with these tests among the patients without cancer.

Level of CNV in the urine sample compared with the grade of the tumor confirmed by histopathologic examination

Level of CNV in the urine sample compared with the stage of the tumor confirmed by histopathologic examination

Number of patients "declared positive" with the UroCAD analysis versus patients "declared positive" with the urine cytology or CTU, and number of patients "declared negative" with the UroCAD analysis versus patients " declared negative " with the urine cytology or CTU.

Changhai Hospital

M.D., Ph.D

Rectal Neoplasms

Colorectal Neoplasms

Intestinal Neoplasms

Intestinal Diseases

Rectal Diseases

no intervention

89 patients with distal sigmoid and rectal cancer were referred in our observation and underwent MS-CTA between June 2020 and March 2022. We classified the distribution of LCA and confirmed whether there exists AMCA (accessory middle colic artery). Then we planned blood flow path based on the classification of LCA branches before operation. High ligation was applied in regular radical surgery. During operation, we carefully protect the bifurcation of ascending and descending LCA. Then we compared the planned blood flow path with the actual postoperative blood flow path to verify the mechanism we proposed previously.

Blood Flow Path Reconstruction in Rectal Cancer

Blood Flow Path Reconstruction in Rectal Cancer After High IMA Ligation Through Preoperative and Postoperative Comparison by Manual Subtraction CTA

It will be available when our paper is accepted.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Clinical Significance of Computer Aided Image Analysis in Treatment Response Evaluation of Lung Cancer	NCT03954847	Lung Cancer		18 Years -	Wuhan Union Hospital, China
HP Pyruvate MRI in Cancers	NCT05697406	Image Warburg Effect Tumors	Hyperpolarized ...	18 Years - 88 Years	University of Maryland, Baltimore
Unnecessary Mastectomy Due to False Size Prediction by Preoperative Imaging Studies in Breast Cancer	NCT04689529	Breast Cancer Surgery IMAGE Chemotherapy Ef...	Preoperative im...	20 Years -	Seoul National University Hospital
Prediction of Upgrade to Invasive Cancer in Patients Diagnosed With Ductal Carcinoma in Situ by Percutaneous Core Needle Biopsy	NCT04498611	Carcinoma, Duct... Invasive Breast... IMAGE	contrast-enhanc...	19 Years -	Seoul National University Hospital
AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy	NCT06035250	Gastric Cancer Image Pathology	Neoadjuvant Che...	18 Years -	Chinese Academy of Sciences
AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy	NCT06035250	Gastric Cancer Image Pathology	Neoadjuvant Che...	18 Years -	Chinese Academy of Sciences
Fluorescence-guided Resection Of Colorectal Liver Metastases Using SGM-101 and Indocyanine GREEN	NCT05965817	Colorectal Canc... Liver Metastasi... Image	SGM-101 op top ...	18 Years -	Leiden University Medical Center
Unnecessary Mastectomy Due to False Size Prediction by Preoperative Imaging Studies in Breast Cancer	NCT04689529	Breast Cancer Surgery IMAGE Chemotherapy Ef...	Preoperative im...	20 Years -	Seoul National University Hospital
HP Pyruvate MRI in Cancers	NCT05697406	Image Warburg Effect Tumors	Hyperpolarized ...	18 Years - 88 Years	University of Maryland, Baltimore
Clinical Significance of Computer Aided Image Analysis in Treatment Response Evaluation of Lung Cancer	NCT03954847	Lung Cancer		18 Years -	Wuhan Union Hospital, China
UroCAD Assay Combined With Computed Tomography Urography and Urine Cytology for UTUC Diagnosis.	NCT05043662	Urothelial Carc... Diagnoses Disea... Ureter Cancer IMAGE Cytology	UroCAD assay, C...	18 Years -	Changhai Hospital
Blood Flow Path Reconstruction in Rectal Cancer	NCT05674097	Rectal Cancer Surgery Image	no intervention	39 Years - 81 Years	Shandong First Medical University

Spots Global Cancer Trial Database for image

Every month we try and update this database with for image cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for image

Every month we try and update this database with for image cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for image cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.